Navigation Links
Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action
Date:11/14/2013

SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Vical Incorporated (NASDAQ: VICL) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of California.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between February, 8, 2012 and August 12, 2013 (the "Class Period").  Vical engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. Vical's lead drug candidate, Allovectin, is a Phase 3 clinical trial product to treat metastatic melanoma.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Vical Accused of Misleading Investors Regarding Its Ability to Obtain FDA Approval for Allovectin

Shares of Vical fell $2.05, or 57%, to close at $1.53 on August 12, 2013, after the company announced that the top-line results from the company's Phase 3 trial of Allovectin failed to demonstrate a significant improvement over chemotherapy.

According to the complaint, the company made false and misleading statements and/or failed to disclose material adverse facts about the company's business prospects and financial condition. Specifically, the complaint alleges that, throughout the Class Period, Vical misled investors about the efficacy of Allovectin and the likelihood of its success in the Phase 3 trial.  Further, the complaint alleges that the company deliberately delayed the announcement of the results of the Allovectin trial to avoid revealing the truth to the market.

Vical Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Vical and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: http://www.robbinsarroyo.com/shareholders-rights-blog/vical-incorporated/

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com


'/>"/>
SOURCE Robbins Arroyo LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Snap to attention: Polymers that react and move to light
2. Patient in vegetative state not just aware, but paying attention
3. Children with diplegic and hemiplegic cerebral palsy: Who can be paid more attention by rehabilitation physicians?
4. Strax Rejuvenation Releases a New Radio Ad that is Getting a Lot of Attention from Listeners
5. Researchers uncover cellular mechanisms for attention in the brain
6. Choline intake improves memory and attention-holding capacity
7. Science academies issue G-Science statements to call world leaders attention to global challenges
8. Pay attention: How we focus and concentrate
9. Hogging the spotlight: South Farms pig gets international attention
10. Top 10 new species list draws attention to diverse biosphere
11. Groundbreaking discovery of the cellular origin of cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark ... today the promotion of two long-standing principal investigators (PI) to the roles of ... Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in the ...
Breaking Biology Technology: